Affinity-purified polyclonal antibodies directed against human lymphoblastoid interferon (IFN), Escherichia coli-derived human or 
It appears that the interaction of interferons (IFNs) with a small number of high-affinity binding sites present on the surfaces of sensitive cells is sufficient to activate cellular genes and to induce an antiviral state (1, 2) . However, it is unknown how the small number of ligand-binding receptors transfers signals from the plasma membrane to intracellular compartments. It is possible that the generation of such signals is the sole property of the receptor molecules and that the ligand itself has no other role than activating receptors by specifically binding to them. However, it has recently been shown that receptor-bound IFNs are internalized and degraded by certain cells (3, 6, 13) and that internalization follows a specific pathway known as concentrative adsorptive (receptor-mediated) endocytosis (13) . Therefore, it is conceivable that IFNs or their degradation products are delivered to the cytoplasm (and perhaps to the nucleus), where they could directly interact with host regulatory mechanisms. Such a cytoplasmic site of action has for instance been described for diphtheria toxin, which is likewise internalized by receptor-mediated endocytosis. It has been shown that introduction of antibodies to diphtheria toxin into cells protects these cells against the lethal effect of subsequent exposure to the toxin (12) .
To investigate a potential cytoplasmic or intranuclear site of action of IFNs, we microinjected specifically purified polyclonal antibodies to IFN into cells before treating the cells with IFN. The following preparations of antibodies were used for these studies. (i) Sheep serum obtained after immunization with purified human (Hu) IFN-a lymphoblastoid (ly) was fractionated as described previously (14 affinity chromatography with an affinity column containing fragments 24 to 81. (iv) Rabbit serum against a synthetic fragment corresponding to residues 111 to 166 of Hu IFN-a1 (4, 5) was affinity purified over fragment 111 to 166. Antisera (iii) and (iv) were specific for the corresponding fragments when tested in radioimmunoassays and bound native Hu IFN-ao to the same extent when tested by immunoprecipitation (data not shown). Endpoint neutralization of 5 pM Hu IFN-ao (0.1 ng/ml) was achieved with 1.6 and 0.8 ng of IgG per ml, respectively.
All antibody preparations were dialyzed against 0.14 M KCl-0.002 M piperazine N,N'-bis(2-ethanesulfonic acid), pH 7.6, and injected by manual needle microinjection (7) at a concentration of 1 or 5 mg/ml into the cytoplasm or the nucleus of Madin-Darby bovine kidney (MDBK) cells, which were maintained in half-confluent monolayers in Dulbecco modified minimal essential medium (16) . After injection, the cells were cultured at 37°C for 1 h. They were then exposed to Hu IFN-a (ly) (2 x 108 U/mg of protein), recombinant Hu IFN-a2 (1.5 x 108 U/mg of protein), or recombinant Hu IFNa, (108 U/mg of protein). Cells either were treated with IFNs continuously for 6 h at 37°C or were exposed to IFNs at 4°C for 2.5 h, washed, and then shifted to 37°C for 6 to 10 h. Cells were then infected (per cell) with 10 PFU of vesicular stomatitis virus (VSV) plaque purified three times in MDBK cells. They were washed after 1 h, incubated for another 3 h at 37°C, fixed with 2% formaldehyde in phosphate-buffered saline (pH 7.4) for 15 min, permeabilized with 0.05% Triton X-100 in phosphate-buffered saline for 5 min, and processed for immunofluorescence by double labeling in the following way. VSV N protein (3a) and with rhodamine-conjugated rabbit antimouse IgG (when sheep antibodies had been injected) or fluorescein-conjugated goat antimouse IgG (when rabbit antibodies had been injected). Cells were observed with a Zeiss photoscope III equipped for epifluorescence. Figure 1 shows the immunofluorescent appearance of cells into which sheep anti-Hu IFN-a (ly) antibodies had been injected before treatment with IFN and subsequent infection with VSV. Figure la shows the intracellular localization of these antibodies after microinjection into the cytoplasm or, in a single cell, into the nucleus (arrow), treatment with Hu IFN-a (ly) (0.5 ng/ml) for 6 h, and infection with VSV for 4 h. Figure lb The quantitative analysis of the effect of injected antibodies on IFN action against VSV depended on the suitability of VSV N protein staining as an IFN assay at the single-cell level. Therefore, we compared the sensitivity of this immunofluorescence assay with that of a conventional cytopathic effect reduction assay performed with Hu IFN-a2 on MDBK cells as described previously (16 were present in the cytoplasm, i.e., antibodies were in ca. 1,000-fold molar excess over the maximum amount of IFN molecules potentially found in the cytoplasm. From the results in Table 1 , it is clear that the injection of these antibodies into the cytoplasm or the nucleus had no effect on the action of IFN.
It is conceivable that IFN may not reach the cytoplasm (or the nucleus) in intact form but that proteolytic degradation products of IFN may enter the intracellular compartment. Antibodies to the native IFNs may not recognize such IFN fragments. Therefore, we also used antibodies made specifically against IFN fragments. From a number of structure and function studies of IFNs, it became clear that the first 15 to 20 amino-terminal amino acids of Hu IFN-a2 are not necessary for bioactivity (15) . Also, from the primary structure of a and ,B IFNs (which apparently bind to the same cellular surface receptor and show similar antiviral activities) it is known that regions of maximum homology are found within both the amino-terminal and the carboxylterminal halves of the molecules. As homologous domains of IFNs may play a more important role in biofunction than heterologous regions, two fragments covering the regions of greatest homology in IFNs (residues 24 to 81 and 111 to 166 of Hu IFN-a1) were chosen for antibody production. As mentioned above, the two antifragment antibody preparations, purified on affinity columns containing the respective fragments, neutralized IFNs to the same extent. Approximately 25% of these antibodies retained on fragment columns were retained on an affinity column containing native full-length IFN (data not shown). This indicates that ca. 75% of these antibodies may recognize determinants not usually accessible or present on native IFN molecules and may thus recognize determinants on fragmented IFNs. Table 2 shows the results of microinjection of these antibodies into the cytoplasm. Treatment of injected control cells with Hu IFN-al resulted in less efficient protection than did treatment with similar concentrations of Hu IFN-a2.
This difference may reflect the lower specific activity of Hu IFN-a1 on MDBK cells (10) . Nevertheless, it is clear that microinjection of the two antifragment antibody preparations had no effect on the establishment of the antiviral state by IFN. Injection of antibodies into the nucleus was likewise without effect (data not shown). 
